Literature DB >> 6320258

Hepatocellular carcinoma treated by transcatheter arterial embolization: progress evaluated by computed tomography.

S Furui, K Otomo, Y Itai, M Iio.   

Abstract

Computed tomography (CT) was performed after 65 transcatheter arterial embolizations (TAE) in 50 patients with hepatocellular carcinoma. Nonenhanced high-density areas were seen in the tumors within 3 days in 17/25 cases (though they soon disappeared) and low-density areas within 2 weeks in 62/65. Gas bubbles were seen in these areas within 2 weeks in 60% of embolizations. Within 3 to 6 months after the first TAE, enhanced lesions developed around or inside the low-density areas in 15/22 patients. Complications appearing within 2 weeks included non-enhanced low-density areas in the liver and spleen, gallbladder thickening, swelling of the head of the pancreas, contrast retention in the kidneys and gallbladder, ascites, and pleural effusion.

Entities:  

Mesh:

Year:  1984        PMID: 6320258     DOI: 10.1148/radiology.150.3.6320258

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

1.  Transcatheter arterial embolization in unresectable hepatocellular carcinoma.

Authors:  R Yamada; K Kishi; T Sonomura; M Tsuda; S Nomura; M Satoh
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Jun-Jul       Impact factor: 2.740

Review 2.  Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.

Authors:  Ania Kielar; Kathryn J Fowler; Sara Lewis; Vahid Yaghmai; Frank H Miller; Hooman Yarmohammadi; Charles Kim; Victoria Chernyak; Takeshi Yokoo; Jeffrey Meyer; Isabel Newton; Richard K Do
Journal:  Abdom Radiol (NY)       Date:  2018-01

3.  Fatal septic complication of transcatheter chemoembolization for hepatocellular carcinoma.

Authors:  T Hashimoto; T Mitani; H Nakamura; S Hori; T Kozuka; Y Kobayashi; A Nakata; T Tsujimura
Journal:  Cardiovasc Intervent Radiol       Date:  1993 Sep-Oct       Impact factor: 2.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.